‘We’ve just had to hit the ground running’: Health professionals’ experiences of cancer immunotherapy: A qualitative study

S Jennings¹, S Anstey¹, J Bower², T Watts¹
¹School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff University, UK
²Chemotherapy Day Unit, Hywel Dda University Health Board
Contact: jenningssj1@cardiff.ac.uk

Background and Aims

• Cancer immunotherapy is transforming outcomes for some people affected by cancer [1], with trials demonstrating clinical benefit across cancers [2-3].
• We have limited knowledge about oncology health professionals’ (HCPs) experiences of these treatments.
• Our qualitative study is investigating patients’ and HCP’s experiences of cancer immunotherapy and HCP’s education, training and support needs.

Methods

• Sampling: purposive and snowball via social media (Twitter) and established oncology networks
• Eligibility: registered practitioners (UK-based); experience supporting people affected by cancer; able and willing to provide informed consent
• Participants: (n=16). UK HCPs (3 consultant oncologists, 11 nurses, 2 pharmacists) from oncology services and secondary care. Including clinical nurse specialists (site-specific, immunotherapy and acute), oncologists, advanced nurse practitioners, nurse consultants, cancer pharmacists
• Semi-structured telephone interviews: conducted between May and October 2020
• Analysis: Reflexive thematic analysis [4].

Key early findings

• HCPs view immunotherapy as a ‘game changer’ treatment, with positive perceptions of improved life expectancy and quality of life.
• However, substantial complexities remain around toxicity management. Equipoise exists between positive outcomes and immune-related adverse events, of which severe cases were experienced.
• Immunotherapy is described as a ‘minefield’, in constant flux and development.
• Highly variable awareness of unique treatment context of immunotherapy exists across HCP groups. Some staff within oncology considered primary care and general medicine colleagues to have limited insight, understanding and awareness.
• Boundaries between roles of different staff were fixed. Clear signposting processes existed for psychological support to site-specific CNS staff and cancer key workers, or specialist services.
• Education and training needs are complex and difficult to identify across HCP groups within oncology services and secondary care. Complexity of training is exacerbated by difficulty raising awareness of immunotherapy in general medicine due to frequent rotations and prevalence of chemotherapy in oncology training.
• Covid-19 impact: Positives: patients can have treatment closer to home; treatments are being fast-tracked; Negatives: assessment delays; digital exclusions mean patients who cannot access video conferencing may not receive same care as those with telephone only.

Conclusion

• Further research should consider how HCP’s ongoing education and training needs in holistic supportive care for cancer immunotherapy should be co-produced in its design, delivery and evaluation.

References


Funded By:

#NCRIVirtual

calendar.ncri.org.uk